BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Torutamig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Torutamig\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07742215-3129@assetmemo.bio
DTSTAMP:20261121T004553Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Torutamig: Phase 3 readout est. (NCT07742215)
DESCRIPTION:Torutamig\, phase 3\, Multiple Myeloma.\nStudy: A Study of the 
 Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients
  With Relapsed or Refractory Multiple Myeloma (AMMADINA)\nEstimated primar
 y completion: July 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/torutamig#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07742215
URL:https://assetmemo.bio/drug/torutamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
